对杰弗里·格雷厄姆、奥马尔·阿卜杜勒-拉赫曼、托尼·K·乔埃里和丹尼尔·Y.C.亨格致编辑的信的回复：关于法比奥·孔福尔蒂、劳拉·帕拉、文森佐·巴尼亚迪等人的《癌症免疫治疗疗效与患者性别：系统评价与荟萃分析》。《柳叶刀·肿瘤学》2018年；19:737 - 46：按性别划分的转移性肾细胞癌结局：国际转移性肾细胞癌数据库联盟的对比结果 - Suppr | 超能文献

相似文献

1

Reply to Jeffrey Graham, Omar Abdel-Rahman, Toni K. Choueiri, and Daniel Y.C. Heng's Letter to the Editor re: Fabio Conforti, Laura Pala, Vincenzo Bagnardi, et al. Cancer Immunotherapy Efficacy and Patients' Sex: A Systematic Review and Meta-analysis. Lancet Oncol 2018;19:737-46: Outcomes of Metastatic Renal Cell Carcinoma by Gender: Contrasting Results from the International mRCC Database Consortium.对杰弗里·格雷厄姆、奥马尔·阿卜杜勒-拉赫曼、托尼·K·乔埃里和丹尼尔·Y.C.亨格致编辑的信的回复：关于法比奥·孔福尔蒂、劳拉·帕拉、文森佐·巴尼亚迪等人的《癌症免疫治疗疗效与患者性别：系统评价与荟萃分析》。《柳叶刀·肿瘤学》2018年；19:737 - 46：按性别划分的转移性肾细胞癌结局：国际转移性肾细胞癌数据库联盟的对比结果

Eur Urol. 2019 Feb;75(2):e34-e35. doi: 10.1016/j.eururo.2018.08.034. Epub 2018 Sep 14.

2

Re: Fabio Conforti, Laura Pala, Vincenzo Bagnardi, et al. Cancer Immunotherapy Efficacy and Patients' Sex: A Systematic Review and Meta-analysis. Lancet Oncol 2018;19:737-46: Outcomes of Metastatic Renal Cell Carcinoma by Gender: Contrasting Results from the International mRCC Database Consortium.回复：法比奥·孔福尔蒂、劳拉·帕拉、文森佐·巴尼亚迪等。癌症免疫治疗疗效与患者性别：系统评价与荟萃分析。《柳叶刀·肿瘤学》2018年；19:737 - 46：转移性肾细胞癌按性别划分的结局：国际转移性肾细胞癌数据库联盟的对比结果

Eur Urol. 2018 Dec;74(6):e139-e140. doi: 10.1016/j.eururo.2018.07.004. Epub 2018 Jul 18.

3

Reply to Roberto Iacovelli, Walter Artibani, and Giampaolo Tortora's Letter to the Editor re: Ian D. Davis, Wanling Xie, Carmel Pezaro, et al. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. Eur Urol 2017;71:970-8.致罗伯托·亚科韦利、沃尔特·阿尔蒂巴尼和詹保罗·托尔托拉给编辑的信的回复，主题为：伊恩·D·戴维斯、谢婉玲、卡梅尔·佩扎罗等人。根据国际转移性肾细胞癌数据库联盟预后分类中与基线的变化评估二线靶向治疗对肾细胞癌的疗效。《欧洲泌尿外科杂志》2017年；71卷：970 - 978页

Eur Urol. 2017 Jun;71(6):e177-e178. doi: 10.1016/j.eururo.2016.12.013. Epub 2016 Dec 29.

4

Re: Toni K. Choueiri, Daniel Y.C. Heng, Jae Lyun Lee, et al. Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial. JAMA Oncol. In press. https://doi.org/10.1001/jamaoncol.2020.2218: SAVOIR: From Own Goal to Winning Goal?

Eur Urol Oncol. 2020 Aug;3(4):561-562. doi: 10.1016/j.euo.2020.06.008. Epub 2020 Jul 9.

5

Reply to Binghao Zhao, Hao Xing, and Wenbin Ma's Letter to the Editor re: Matthew S. Ernst, Vishal Navani, J. Connor Wells, et al. Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma. Eur Urol. 2023;84:109-116.回复赵炳浩、邢浩和马文斌致编辑的信，内容涉及：马修·S·恩斯特、维沙尔·纳瓦尼、J·康纳·韦尔斯等人。国际转移性肾细胞癌数据库联盟预后分组在当代转移性肾细胞癌一线联合治疗中的结果。《欧洲泌尿外科杂志》。2023年；84卷：109 - 116页。

Eur Urol. 2023 Jul;84(1):e18-e19. doi: 10.1016/j.eururo.2023.03.032. Epub 2023 Apr 18.

6

Re: Brian I. Rini, Tanya B. Dorff, Paul Elson, et al. Active Surveillance in Metastatic Renal-cell Carcinoma: A Prospective, Phase 2 Trial. Lancet Oncol Lancet 2016;17:1317-24: Active Surveillance in Metastatic Renal Cell Carcinoma: Option or Exception?回复：布莱恩·I·里尼、坦尼娅·B·多尔夫、保罗·埃尔森等。转移性肾细胞癌的主动监测：一项前瞻性2期试验。《柳叶刀·肿瘤学》，《柳叶刀》2016年；17:1317 - 24：转移性肾细胞癌的主动监测：是一种选择还是例外？

Eur Urol. 2017 May;71(5):e139-e140. doi: 10.1016/j.eururo.2016.09.034. Epub 2016 Sep 29.

7

Re: Rana R. McKay, Xun Lin, Julia J. Perkins, Daniel Y.C. Heng, Ronit Simantov, Toni K. Choueiri. Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma. Eur Urol 2014;66:502-9.回复：拉娜·R·麦凯、林勋、朱莉娅·J·珀金斯、丹尼尔·Y·C·亨、罗尼特·西曼托夫、托尼·K·乔艾里。肾细胞癌患者骨转移及双膦酸盐治疗的预后意义。《欧洲泌尿外科杂志》2014年；66卷：502 - 509页

Eur Urol. 2014 Sep;66(3):e53-4. doi: 10.1016/j.eururo.2014.04.019. Epub 2014 May 2.

8

Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model.分子亚型提高国际转移性肾细胞癌数据库联盟预后模型的预后价值。

Oncologist. 2017 Mar;22(3):286-292. doi: 10.1634/theoncologist.2016-0078. Epub 2017 Feb 20.

9

Reply to Fabio Zattoni, Filiberto Zattoni, and Laura Evangelista's Letter to the Editor re: Marlon Perera, Nathan Papa, Daniel Christidis, et al. Sensitivity, Specificity, and Predictors of Positive Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol 2016;70:926-37.回复法比奥·扎托尼、菲利贝托·扎托尼和劳拉·埃万杰利斯塔致编辑的信，信中提及马龙·佩雷拉、内森·帕帕、丹尼尔·克里斯蒂迪斯等人的文章：《晚期前列腺癌中镓标记前列腺特异性膜抗原正电子发射断层扫描的敏感性、特异性及阳性预测因素：一项系统评价和荟萃分析》。《欧洲泌尿外科杂志》2016年；70卷：926 - 937页。

Eur Urol. 2017 Feb;71(2):e66-e67. doi: 10.1016/j.eururo.2016.08.050. Epub 2016 Sep 3.

10

Overall survival after immunotherapy, tyrosine kinase inhibitors and surgery in treatment of metastatic renal cell cancer: outcome of 143 consecutive patients from a single centre.免疫疗法、酪氨酸激酶抑制剂及手术治疗转移性肾细胞癌后的总生存期：来自单一中心的143例连续患者的治疗结果

Scand J Urol. 2014 Aug;48(4):379-86. doi: 10.3109/21681805.2013.876550. Epub 2014 Feb 12.

引用本文的文献

1

Sex and Gender Differences in Kidney Cancer: Clinical and Experimental Evidence.肾癌中的性别差异：临床与实验证据

Cancers (Basel). 2021 Sep 13;13(18):4588. doi: 10.3390/cancers13184588.

2

Comparative Efficacy and Safety of Immunotherapy Alone and in Combination With Chemotherapy for Advanced Non-small Cell Lung Cancer.免疫疗法单独及联合化疗治疗晚期非小细胞肺癌的疗效和安全性比较

Front Oncol. 2021 Mar 18;11:611012. doi: 10.3389/fonc.2021.611012. eCollection 2021.

3

Gender-Related Approach to Kidney Cancer Management: Moving Forward.